shutterstock_1664830000_sundry_photography
Sundry Photography / Shutterstock.com
11 May 2023Big PharmaLiz Hockley

Gilead defeats US govt in billion-dollar HIV drug patent suit

Jury finds three US government patents over PrEP to be invalid | Case thought to be the first time US government has sued a pharmaceutical firm over patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
4 July 2023   Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.
Big Pharma
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Americas
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More on this story

Big Pharma
4 July 2023   Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.
Big Pharma
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Americas
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More on this story

Big Pharma
4 July 2023   Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.
Big Pharma
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Americas
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.